NCT06162377 2025-12-17
Methylnatrexone In Resectable Head and Neck Squamous Cell Carcinoma (MINK). A "Window of Opportunity" Pilot Study.
M.D. Anderson Cancer Center
Phase 4 Recruiting
M.D. Anderson Cancer Center
Bausch Health Americas, Inc.
Bausch Health Americas, Inc.
Bausch Health Americas, Inc.
University of Vermont